Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic ...(pany and is based in S. Mamede doCoronad...),Health

It is the partner of choice for many companies, having a strong presence in the Iberian peninsula as well as in over 10 countries in Latin America and in around 20 French or Portuguese speaking African countries.

BIAL is strongly committed to therapeutic innovation investing approximately 20% of its turnover in research and development every year. Key research areas for BIAL are the central nervous system, the cardiovascular system and allergology. BIAL currently has several other innovative programs under development, which the company expects to bring to the market within the next years, thereby strengthening its position throughout Europe.

Further information about BIAL can be found at http://www.bial.com

References:

1. Elger C, Halász P, Moreira J et al. Long-term add-on treatment of partial epilepsy with eslicarbazepine acetate. Abstract presented at the 28th International Epilepsy Congress, Budapest, Hungary, 28 June 2009 - 2 July 2009.

2. Brodie MJ. Management strategies for refractory localization-related seizures. Epilepsia 2001; 42(Suppl 3):27-30.

3. Halász P, Elger C, Ben-Menachem E et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment to carbamazepine in patients with partial-onset seizures. Abstract presented at the 28th International Epilepsy Congress, Budapest, Hungary, 28 June 2009 - 2 July 2009.

4. Gama H, Elger C, Halász P et al. Time of occurence of adverse events in relation to start of treatment with eslicarbazepine acetate as add-on treatment in patients with partial-onset seizures. Abstract presented at the 28th International Epilepsy Congress, Budapest, Hungary, 28 June 2009 - 2 July 2009.

5. Elger C, French J, Halasz P. et al. Evaluation of Eslicarbazepine Acetate as Add-On T
'/>"/>